Amid a closely watched legal battle, Amgen (AMGN) has joined the growing ranks of major drug makers curtailing the discounts offered through a federal program for safety-net hospitals and clinics.
As of Jan. 3, 2022, the company will no longer offer discounts to contract pharmacies used by hospitals and clinics that serve low-income populations and purchase medicines under the 340B Drug Discount Program, according to a letter sent by Amgen. The program requires drug makers to offer discounts that are typically estimated to be 25% to 50% — but could be much higher — on all outpatient drugs. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. What’s included? Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. This name will appear with your comment
https://www.statnews.com/pharmalot/2021/12/01/amgen-340b-hospitals-merck-sanofi-lilly-novartis/
